Skip to main content
SpringerLink
Log in

Future Clinical and Professional Directions in Cardio-oncology

  • Chapter
  • First Online:
Cardio-Oncology

  • 875 Accesses

Abstract

With the availability of new and very effective therapies, cancer has increasingly become a chronic condition and led to the need for close collaboration between the specialties of oncology and cardiology. Collaboration is developing in the clinic, research, and training arenas and has drawn the attention of major national and international cardiology and oncology associations to the field of cardio-oncology. This chapter discusses how the partnership of these two medical subspecialties in the future will improve outcomes for cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65:2739–46.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56(20):1644–50. doi:10.1016/j.jacc.2010.07.023.

    Article  PubMed  Google Scholar 

  3. Ammon M, Arenja N, Leibundgut G, Buechel RR, Kuster GM, Kaufmann BA, Pfister O. Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice. J Card Fail. 2013;19(9):629–34. doi:10.1016/j.cardfail.2013.07.007.

    Article  PubMed  Google Scholar 

  4. Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst. 2014;106(9):pii: dju232.

    Google Scholar 

  5. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21.

    Article  CAS  PubMed  Google Scholar 

  6. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80. doi:10.1093/eurheartj/ehw022.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Pituskin E, Mackey JR, Koshman S, Jassal DS, Pitz M, et al. Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized clinical trial. Proceedings of the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium Abstract (S1-05). 2015.

    Google Scholar 

  9. Williams ES, Halperin JL, Fuster V. ACC 2015 COre CArdiovascular Training Statement (COCATS 4) (Revision of COCATS 3). J Am Coll Cardiol. 2015;65(17):1721–3.

    Article  Google Scholar 

  10. Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-oncology training: a proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a new multidisciplinary specialty. J Card Fail. 2016;22(6):465–71. doi:10.1016/j.cardfail.2016.03.012.

    Article  PubMed  Google Scholar 

  11. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013;26:1013–32.

    Article  PubMed  Google Scholar 

  12. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.

    Article  PubMed  Google Scholar 

  13. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155–66.

    Article  PubMed  Google Scholar 

  14. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1–10.

    Article  PubMed  Google Scholar 

  15. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128:1927–95.

    Article  PubMed  Google Scholar 

  16. Iliescu C, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, et al. SCAI expert consensus statement-executive summary evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2015;87(5):895–9.

    Article  PubMed  Google Scholar 

  17. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. ASCO clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Oncol Pract. 2007;3:233–5.

    Article  Google Scholar 

  18. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Relevant disclosures and relationship with industry: Ana Barac has received research support from the NIH, research support and honoraria for lectures from Genentech Inc., and consultancy fees from Cell Therapeutics, Inc. Erica L. Mayer has received research support from Pfizer, Eisai, and Myriad.

Author information

Authors and Affiliations

  1. MedStar Heart and Vascular Institute, Medstar Washington Hospital Center, Washington, DC, USA

    Ana Barac

  2. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Erica L. Mayer

Authors
  1. Ana Barac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erica L. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Barac .

Editor information

Editors and Affiliations

  1. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

    Gretchen G. Kimmick

  2. Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Daniel J. Lenihan

  3. Maine Medical Center, Cardiovascular Institute, Portland, Maine, USA

    Douglas B. Sawyer

  4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

    Erica L. Mayer

  5. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA

    Dawn L. Hershman

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

(PPTX 834 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Barac, A., Mayer, E.L. (2017). Future Clinical and Professional Directions in Cardio-oncology. In: Kimmick, G., Lenihan, D., Sawyer, D., Mayer, E., Hershman, D. (eds) Cardio-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-43096-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43096-6_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43094-2

  • Online ISBN: 978-3-319-43096-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation